Tumor Biology

, Volume 35, Issue 10, pp 10503–10513 | Cite as

Promoter methylation and polymorphism of E-cadherin gene may confer a risk to prostate cancer: a meta-analysis based on 22 studies

  • Zheng Chang
  • Hongbing Zhou
  • Yi Liu
Research Article


Emerging evidence has suggested that −160C/A polymorphism and promoter methylation of E-cadherin gene may contribute to the risk of prostate cancer. However, the results are still conflicting. We aim to systematically evaluate the potential of promoter methylation and polymorphism in E-cadherin gene to confer a risk to prostate cancer through meta-analysis. PubMed, Embase, Web of Science, Cochrane Library, and Chinese National Knowledge Infrastructure (CNKI) databases were searched to identify eligible studies published before April 1, 2014. Pooled odds ratios (ORs) with their 95 % confidence intervals (95 % CIs) were calculated by using the random-effect model or the fixed-effect model, according to heterogeneity test. Subgroup analyses were also performed to explore the potential sources of heterogeneity. Sensitivity and publication bias analyses were used to test the robustness of our results. We performed a meta-analysis of 22 included studies, with 11 on −160C/A polymorphism and another 11 on promoter methylation of E-cadherin gene. Our meta-analysis results suggested that E-cadherin −160C/A polymorphism may be a potential risk factor for prostate cancer. Furthermore, we observed that the frequencies of promoter methylation of E-cadherin gene in the prostate cancer tissues were significantly higher than those of normal tissues, indicating that promoter methylation of E-cadherin gene may play an important role in prostate carcinogenesis. In conclusion, the present meta-analysis provides further evidence that promoter methylation and −160C/A polymorphism of E-cadherin gene may confer a risk to prostate cancer. Identifying these risk factors for prostate cancer will improve early detection, allow for selective chemoprevention, and provide further insights into its disease mechanisms.


E-cadherin Polymorphism Promoter methylation Prostate cancer Meta-analysis 


Conflicts of interest



  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.CrossRefPubMedGoogle Scholar
  3. 3.
    Filella X, Alcover J, Molina R. Active surveillance in prostate cancer: the need to standardize. Tumour Biol. 2011;32:839–43.CrossRefPubMedGoogle Scholar
  4. 4.
    Wong YN, Mitra N, Hudes G, Localio R, Schwartz JS, Wan F, et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA. 2006;296:2683–93.CrossRefPubMedGoogle Scholar
  5. 5.
    Gotay CC, Holup JL, Pagano I. Ethnic differences in quality of life among early breast and prostate cancer survivors. Psychooncology. 2002;11:103–13.CrossRefPubMedGoogle Scholar
  6. 6.
    Gronberg H. Prostate cancer epidemiology. Lancet. 2003;361:859–64.CrossRefPubMedGoogle Scholar
  7. 7.
    Sankpal UT, Pius H, Khan M, Shukoor MI, Maliakal P, Lee CM, et al. Environmental factors in causing human cancers: emphasis on tumorigenesis. Tumour Biol. 2012;33:1265–74.CrossRefPubMedGoogle Scholar
  8. 8.
    Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet. 2008;40:310–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med. 2008;358:910–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Hunter DJ, Riboli E, Haiman CA, Albanes D, Altshuler D, Chanock SJ, et al. A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer. 2005;5:977–85.CrossRefPubMedGoogle Scholar
  11. 11.
    Shields PG, Harris CC. Cancer risk and low-penetrance susceptibility genes in gene–environment interactions. J Clin Oncol. 2000;18:2309–15.PubMedGoogle Scholar
  12. 12.
    Berx G, Becker KF, Hofler H, van Roy F. Mutations of the human E-cadherin (CDH1) gene. Hum Mutat. 1998;12:226–37.CrossRefPubMedGoogle Scholar
  13. 13.
    More H, Humar B, Weber W, Ward R, Christian A, Lintott C, et al. Identification of seven novel germline mutations in the human E-cadherin (CDH1) gene. Hum Mutat. 2007;28:203.CrossRefPubMedGoogle Scholar
  14. 14.
    Kuefer R, Hofer MD, Gschwend JE, Pienta KJ, Sanda MG, Chinnaiyan AM, et al. The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer. Clin Cancer Res. 2003;9:6447–52.PubMedGoogle Scholar
  15. 15.
    Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 2008;68:3645–54.CrossRefPubMedGoogle Scholar
  16. 16.
    Wijnhoven BP, Dinjens WN, Pignatelli M. E-cadherin–catenin cell–cell adhesion complex and human cancer. Br J Surg. 2000;87:992–1005.CrossRefPubMedGoogle Scholar
  17. 17.
    Boggon TJ, Murray J, Chappuis-Flament S, Wong E, Gumbiner BM, Shapiro L. C-cadherin ectodomain structure and implications for cell adhesion mechanisms. Science. 2002;296:1308–13.CrossRefPubMedGoogle Scholar
  18. 18.
    Baranwal S, Alahari SK. Molecular mechanisms controlling E-cadherin expression in breast cancer. Biochem Biophys Res Commun. 2009;384:6–11.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Chen B, Zhou Y, Yang P, Liu L, Qin XP, Wu XT. CDH1–160C > A gene polymorphism is an ethnicity-dependent risk factor for gastric cancer. Cytokine. 2011;55:266–73.CrossRefPubMedGoogle Scholar
  20. 20.
    von Burstin J, Eser S, Paul MC, Seidler B, Brandl M, Messer M, et al. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology. 2009;137:361–71, 71 e1–5.Google Scholar
  21. 21.
    Jonsson BA, Adami HO, Hagglund M, Bergh A, Goransson I, Stattin P, et al. −160C/A polymorphism in the E-cadherin gene promoter and risk of hereditary, familial and sporadic prostate cancer. Int J Cancer. 2004;109:348–52.CrossRefPubMedGoogle Scholar
  22. 22.
    Li LC, Chui RM, Sasaki M, Nakajima K, Perinchery G, Au HC, et al. A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res. 2000;60:873–6.PubMedGoogle Scholar
  23. 23.
    Kallakury BV, Sheehan CE, Winn-Deen E, Oliver J, Fisher HA, Kaufman Jr RP, et al. Decreased expression of catenins (alpha and beta), p120 CTN, and E-cadherin cell adhesion proteins and E-cadherin gene promoter methylation in prostatic adenocarcinomas. Cancer. 2001;92:2786–95.CrossRefPubMedGoogle Scholar
  24. 24.
    Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, et al. Strengthening the reporting of genetic association studies (STREGA): an extension of the STROBE statement. Hum Genet. 2009;125:131–51.CrossRefPubMedGoogle Scholar
  25. 25.
    Teo YY, Fry AE, Clark TG, Tai ES, Seielstad M. On the usage of HWE for identifying genotyping errors. Ann Hum Genet. 2007;71:701–3. author reply 4.CrossRefPubMedGoogle Scholar
  26. 26.
    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.CrossRefPubMedGoogle Scholar
  27. 27.
    Jackson D, White IR, Riley RD. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med. 2012;31:3805–20.PubMedCentralCrossRefPubMedGoogle Scholar
  28. 28.
    Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analyses of randomized controlled trials. N Engl J Med. 1987;316:450–5.CrossRefPubMedGoogle Scholar
  29. 29.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295:676–80.CrossRefPubMedGoogle Scholar
  31. 31.
    Bonilla C, Mason T, Long L, Ahaghotu C, Chen W, Zhao A, et al. E-cadherin polymorphisms and haplotypes influence risk for prostate cancer. Prostate. 2006;66:546–56.CrossRefPubMedGoogle Scholar
  32. 32.
    Cybulski C, Wokolorczyk D, Jakubowska A, Gliniewicz B, Sikorski A, Huzarski T, et al. DNA variation in MSR1, RNASEL and E-cadherin genes and prostate cancer in Poland. Urol Int. 2007;79:44–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Forszt P, Pilecka A, Malodobra M, Markowska J, Maksymowicz K, Dobosz T. Single-nucleotide polymorphism association study of VDR and CDH1 genes and the risk of prostate cancer. Adv Clin Exp Med. 2009;18:215–20.Google Scholar
  34. 34.
    Goto T, Nakano M, Ito S, Ehara H, Yamamoto N, Deguchi T. Significance of an E-cadherin gene promoter polymorphism for risk and disease severity of prostate cancer in a Japanese population. Urology. 2007;70:127–30.CrossRefPubMedGoogle Scholar
  35. 35.
    Hajdinjak T, Toplak N. E-cadherin polymorphism— − 160 C/A and prostate cancer. Int J Cancer. 2004;109:480–1.CrossRefPubMedGoogle Scholar
  36. 36.
    Kamoto T, Isogawa Y, Shimizu Y, Minamiguchi S, Kinoshita H, Kakehi Y, et al. Association of a genetic polymorphism of the E-cadherin gene with prostate cancer in a Japanese population. Jpn J Clin Oncol. 2005;35:158–61.CrossRefPubMedGoogle Scholar
  37. 37.
    Lindstrom S, Wiklund F, Jonsson BA, Adami HO, Balter K, Brookes AJ, et al. Comprehensive genetic evaluation of common E-cadherin sequence variants and prostate cancer risk: strong confirmation of functional promoter SNP. Hum Genet. 2005;118:339–47.CrossRefPubMedGoogle Scholar
  38. 38.
    Pookot D, Li LC, Tabatabai ZL, Tanaka Y, Greene KL, Dahiya R. The E-cadherin −160 C/A polymorphism and prostate cancer risk in white and black American men. J Urol. 2006;176:793–6.CrossRefPubMedGoogle Scholar
  39. 39.
    Tsukino H, Kuroda Y, Imai H, Nakao H, Qiu D, Komiya Y, et al. Lack of evidence for the association of E-cadherin gene polymorphism with increased risk or progression of prostate cancer. Urol Int. 2004;72:203–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Verhage BA, van Houwelingen K, Ruijter TE, Kiemeney LA, Schalken JA. Single-nucleotide polymorphism in the E-cadherin gene promoter modifies the risk of prostate cancer. Int J Cancer. 2002;100:683–5.CrossRefPubMedGoogle Scholar
  41. 41.
    Hoque MO, Topaloglu O, Begum S, Henrique R, Rosenbaum E, Van Criekinge W, et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol. 2005;23:6569–75.CrossRefPubMedGoogle Scholar
  42. 42.
    Li C, Zhang X, Chen Z, Ouyang J, Du G, Yang W, et al. A specific methylation pattern of the E-cadherin gene promoter is associated with its expression and the pathological grades in prostate cancer. Chin J Exp Surg. 2000;17:47–8.Google Scholar
  43. 43.
    Li LC, Zhao H, Nakajima K, Oh BR, Ribeiro Filho LA, Carroll P, et al. Methylation of the E-cadherin gene promoter correlates with progression of prostate cancer. J Urol. 2001;166:705–9.CrossRefPubMedGoogle Scholar
  44. 44.
    Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zochbauer-Muller S, Farinas AJ, et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res. 2002;8:514–9.PubMedGoogle Scholar
  45. 45.
    Singal R, Ferdinand L, Reis IM, Schlesselman JJ. Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease. Oncol Rep. 2004;12:631–7.PubMedGoogle Scholar
  46. 46.
    Tilandyova P, Grobarcikova S, Kajo K, Kliment J, Lasabova Z, Zubor P, et al. Detection of methylation of GSTP1, E-cad and PTGS2 in prostate adenocarcinoma and benign prostate hyperplasia. European Urology. 2010;Supplement 9:626–7.Google Scholar
  47. 47.
    Tong Q, Qiu J, Yao L, Huang J, Liu J, Sun R, et al. Pyrosequencing detection of aberrant methylation of GSTP1, CDH1 and p16 genes in prostate cancer. Chin J Med Off. 2013;41:577–9.Google Scholar
  48. 48.
    Vasiljevic N, Wu K, Brentnall AR, Kim DC, Thorat MA, Kudahetti SC, et al. Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis Markers. 2011;30:151–61.CrossRefPubMedGoogle Scholar
  49. 49.
    Woodson K, Hanson J, Tangrea J. A survey of gene-specific methylation in human prostate cancer among black and white men. Cancer Lett. 2004;205:181–8.CrossRefPubMedGoogle Scholar
  50. 50.
    Yao Q, He XS, Zhang JM, He J. Promotor hypermethylation of E-cadherin, p16 and estrogen receptor in prostate carcinoma. Zhonghua Nan Ke Xue. 2006;12:28–31.PubMedGoogle Scholar
  51. 51.
    Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev. 2000;14:2410–34.CrossRefPubMedGoogle Scholar
  52. 52.
    Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010;24:1967–2000.PubMedCentralCrossRefPubMedGoogle Scholar
  53. 53.
    Wang GY, Lu CQ, Zhang RM, Hu XH, Luo ZW. The E-cadherin gene polymorphism 160C → A and cancer risk: a HuGE review and meta-analysis of 26 case–control studies. Am J Epidemiol. 2008;167:7–14. doi: 10.1093/aje/kwm264.CrossRefPubMedGoogle Scholar
  54. 54.
    Wang L, Wang G, Lu C, Feng B, Kang J. Contribution of the −160C/A polymorphism in the E-cadherin promoter to cancer risk: a meta-analysis of 47 case–control studies. PLoS One. 2012;7:e40219. doi: 10.1371/journal.pone.0040219.PubMedCentralCrossRefPubMedGoogle Scholar
  55. 55.
    Qiu LX, Li RT, Zhang JB, Zhong WZ, Bai JL, Liu BR, et al. The E-cadherin (CDH1)— − 160 C/A polymorphism and prostate cancer risk: a meta-analysis. Eur J Hum Genet. 2009;17:244–9. doi: 10.1038/ejhg.2008.157.PubMedCentralCrossRefPubMedGoogle Scholar
  56. 56.
    Deng QW, He BS, Pan YQ, Sun HL, Xu YQ, Gao TY, et al. Roles of E-cadherin (CDH1) genetic variations in cancer risk: a meta-analysis. Asian Pac J Cancer Prev. 2014;15:3705–13.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of UrologyGeneral Hospital of Jinan Military CommandJinanPeople’s Republic of China
  2. 2.Department of General SurgeryPLA 456th HospitalJinanPeople’s Republic of China

Personalised recommendations